O4.2.1 Eosinophil count and inhaled corticosteroids
There is significant interest in the use of blood eosinophil count as both a prognostic marker and to guide the use of inhaled corticosteroids in COPD, but its role is controversial.
In a US cohort study (Zeiger 2018), elevated blood eosinophils at baseline were independently associated with COPD exacerbations and COPD-related ED visits or hospitalisations during a year of follow-up. After adjusting for confounders, rate of future exacerbations were 25%, 48% and 76% greater for patients with eosinophils ≥ 300 cells/ mm³ ≥ 400 cells/ mm³ and ≥ 500 cells/ mm³, respectively. Analysis of data from the COPD Gene and ECLIPSE longitudinal studies (Yun 2018) also found baseline blood eosinophils ≥ 300 cells/ mm³ to be associated with increased exacerbation frequency. In a large group of patients (n=7,180) from the Danish Copenhagen General Population Study (Vedel-Krogh 2018), blood eosinophils ≥ 0.34 x109 cells/L in people whose FEV1 was < 50% predicted were associated with a higher risk of hospitalisation for pneumonia compared with those with the same degree of airflow obstruction but a lower eosinophil count. In the Korean Obstructive Lung Disease cohort study, patients with COPD who had persistently high blood eosinophils (≥ 300 cells/ mm³) had a better survival rate and improved symptoms and quality of life than those with persistently low eosinophil counts (<300 cells/ mm³) while those with variable eosinophil counts had survival rates similar to those with persistently low counts (Shin 2018).
In a post-hoc analysis of the FORWARD study, a double blind randomised controlled study which compared 48 weeks of treatment with extra fine beclomethasone dipropionate (BDP) plus formoterol furoate 100/6 ug two puffs bd with formoterol furoate (FF) 12 ug one puff bd in patients with COPD, patients with eosinophil counts ≥ 279.8 cells/μl experienced the highest exacerbation rate with FF and the greatest benefit from the BDP/FF combination (Siddiqui 2015). In a post-hoc review of data from WISDOM, patients with higher blood eosinophil counts were more likely to develop exacerbations after withdrawal of inhaled corticosteroids, with a significant treatment-by-subgroup interaction above an eosinophil count of 4% or greater or above 300 cells/μL (Watz 2016). Bafadhel et al used negative binomial regression analysis using splines to examine data from RCTs of budesonide/formoterol in patients with COPD, a history of exacerbations and available eosinophil counts (n=4528) (Bafadhel 2018). They found a treatment effect interaction between the budesonide-formoterol combination as compared with formoterol alone and eosinophil count, with respect to exacerbations, lung function and health status. At eosinophil counts of 100/μl or more, a significant treatment effect was found for exacerbation reduction with budesonide/formoterol compared with formoterol alone (RR 0.75, CI 0.57-0.99); p interaction =0.015).
Casanova et al examined the prevalence and stability of the finding of a blood eosinophil count ≥ 300 cells/μl and its relationship to outcomes over two years using Cox hazard analysis in patients from the CHAIN (patients with COPD and smokers without COPD) and BODE (patients with COPD only) cohorts (Casanova 2017). 15.8% of COPD patients in CHAIN and 12.3% of those in BODE had persistently elevated eosinophils during the period of follow-up (at least 3 measurements over two years). A similar eosinophil blood pattern was observed in controls. Exacerbation rates did not differ in patients with and without eosinophilia. All-cause mortality was lower in patients with high eosinophils compared with those with values <300 cells/μL–1 (15.8% versus 33.7%; p=0.026). In the SPIROMICS database of patients with COPD, smokers without COPD and 7% non smokers, blood eosinophil count alone was not a reliable biomarker for COPD severity or exacerbations (Hastie 2017). Although there was a statistically significant relationship between blood and sputum eosinophils, blood eosinophil count did not reliably predict the level of sputum eosinophilia. Sputum eosinophils were available in a subset of just on 1,000 patients. The authors found that high sputum eosinophils, but not blood eosinophils, identified a subset of patients with more severe airflow obstruction, worse quality of life, more emphysema and gas trapping and more exacerbations. However, there were no differences in CAT scores noted with either blood or sputum eosinophil stratification. In the prospective GLUCOLD study of patients with COPD using ICS or placebo during 30 months of follow up, neither baseline blood eosinophil levels nor baseline levels in sputum, bronchoalveolar lavage (BAL) or bronchial biopsy predicted longitudinal changes in FEV1 with or without ICS (Hartjes 2018).
Prospective studies that randomise patients based on eosinophil count are required to confirm these associations.< Prev Next >